Actively Recruiting
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
Led by The University of Texas Medical Branch, Galveston · Updated on 2026-02-23
490
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
CONDITIONS
Official Title
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide and sign informed consent
- Between 18 and 80 years of age
- Have chronic kidney disease defined by glomerular filtration rate
- Surgery requires general anesthesia with endotracheal intubation and neuromuscular blockade
You will not qualify if you...
- Under 18 years old
- Over 80 years old
- Have end stage renal disease
- Require dialysis
- Presenting for renal transplantation
- Pregnant female
- Currently in the correctional system
- Urgent or emergent procedure
- Surgery requires intubation after operation
- Allergy to Rocuronium, Sugammadex, Cisatracurium, or Neostigmine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Texas Medical Branch
Galveston, Texas, United States, 77554
Actively Recruiting
Research Team
M
Michael Kinsky, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here